Here, our in vitro study showed a significant expression of both TLR4 and NFKB after bLf treatment of immune cells from COVID-19 group, as indicated by RMSD value of 0.262 Å for TLR4 from human samples binding to bLf, whereas Ohto et al. The gene discussed is TLR4; the disease is COVID-19.